Former Rhone-Poulenc Rorer chief will head ViroPharma; Michel de Rosen says the small Exton pharmaceutical firm is developing antiviral drugs that show promise
Article Abstract:
Several factors influenced Michel de Rosen to take the president and CEO post of the small Exton drug company, ViroPharma: the firm's size and flexibility along with growth potential, its strong pipeline and its location. The company is getting Pleconaril ready for the FDA's review; it also is developing drugs to treat hepatitis C and respiratory syncytial virus. The company went public in 1996 and has 128 employees, but it has yet to market its first product.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
SmithKline to back Penn's gene program
Article Abstract:
SmithKline Beecham, the global pharmaceutical company, will provide a substantial sum of money to support the gene therapy program of the University of Pennsylvania. Details were not revealed, but the grant will be less than $4million a year and will be for basic research and not human trials.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Glaxo charts its growth strategy
Article Abstract:
GlaxoSmithKline P.L.C. revealed a proposal to delegate early-stage drug development to six small, semiautonomous research groups that will compete for resources within the company and get rewards for their sucesses. The company's two Philadelphia research facilities will house a center within the company's larger research operations.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Clearing the way for new office park at Navy Base; the city will soon prepare 60 acres in the hopes of attractng a developer
- Abstracts: Doylestown firm gets U.S. rebuke on its ad claims; Quigley Corp. will stop making certain statements about the health effects of its Cold-Eeze zinc lozenges